Preparation and in vitro evaluation of chitosan microspheres containing prednisolone: Comparison of simple and conjugate microspheres

Drug Development and Industrial Pharmacy

Volumn 31, Issue 7, 2005, Pages 597-605

  Onishi, Hiraku ^a   Oosegi, Tomoko ^a   Machida, Yoshiharu ^a   McGinity, James W ^b  

^a HOSHI UNIVERSITY   (Japan)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Chitosan microsphere; Conjugate; Drug release; Particle characteristics; Prednisolone

Indexed keywords

1 (3 DIMETHYLAMINOPROPYL) 3 ETHYLCARBODIIMIDE; CHITOSAN; MICROSPHERE; PREDNISOLONE; PREDNISOLONE HEMISUCCINATE;

ARTICLE; COMPARATIVE STUDY; DRUG CONJUGATION; DRUG FORMULATION; DRUG MIXTURE; DRUG RELEASE; ENTERITIS; IN VITRO STUDY; PARTICLE SIZE;

ANTI-INFLAMMATORY AGENTS; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMPOUNDING; IRRITABLE BOWEL SYNDROME; MICROSCOPY, ELECTRON, SCANNING; MICROSPHERES; PARTICLE SIZE; PREDNISOLONE;

EID: 25144499987     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040500216063     Document Type: Article

References (27)

1. Anderson, B. D., & Taphouse, V. (1981). Initial rate studies of hydrolysis and acyl migration in methylprednisolone 21-hemisuccinate and 17-hemisuccinate. Journal of Pharmaceutical Sciences, 70, 181-186.
2. Brzezinski, A., Rankin, G. B., Seidner, D. L., & Lashner, B. A. (1995). Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease. Cleveland Clinic Journal of Medicine, 62, 317-323.
3. Ekstrom, G. M. (1998). Oxazolone-induced colitis in rats: effects of budesonide, cyclosporine A, and 5-aminosalicylic acid. Scandinavian Journal of Gastroenterology, 33, 174-179.
4. Erdmann, L., & Uhrich, K. E. (2000). Synthesis and degradation characteristics of salicylic acid-derived poly(anhydride-esters). Biomaterials, 27, 1941-1946.
5. Galvez, J., Garrido, M., Merlos, M., Torres, M. I., & Zarzuelo, A. (2000). Intestinal anti-inflammatory activity of UR-12746, a novel 5-ASA conjugate, on acute and chronic experimental colitis in the rat. British Journal of Pharmacology, 130, 1949-1959.
6. Kinget, R., Kalala, W., Vervoort, L., & van den Mooster, G. (1998). Colonic drug targeting. Journal of Drug Targeting, 6, 129-149.
7. Kleessen, B., Kroesen, A. J., Buhr, H. J., & Blaut, M. (2002). Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scandinavian Journal of Gastroenterology, 37, 1034-1041.
8. Klotz, U. (1985). Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic add. Clinical Pharmacokinetics, 70, 285-302.
9. Lamprecht, A., Schafer, U., & Lehr, C. M. (2000a). Site specific targeting of microparticles to the inflamed colonic mucosa: a novel approach to the treatment of inflammatory bowel disease. Proceedings of the International Symposium on Controlled Release of Bioactive Materials, 27, 480-481.
10. Lamprecht, A., Schafer, U., & Lehr, C. M. (2000b). Microparticle targeting to the inflamed colonic mucosa for the treatment of inflammatory bowel disease: in vivo results from rat. AAPS PharmSciences, 2(S1), Abstract 1930.
11. Lamprecht, A., Ubrich, N., Yamamoto, H., Schafer, U., Takeuchi, H., Lehr, C. M., Maincent, P., & Kawashima, Y. (2001a). Design of rolipram-loaded nanoparticles: comparison of two preparation methods. Journal of Controlled Release, 71, 297-306.
12. Lamprecht, A., Schafer, U., & Lehr, C. M. (2001b). Size-dependent bioadehesion of micro- and nanoparticles to the inflamed colonie mucosa. Pharmaceutical Research, 18, 788-793.
13. Lamprecht, A., Ubrich, N., Yamamoto, H., Schafer, U., Takeuchi, H., Melia, C., Kawashima, Y., & Lehr, C. M. (2001c). Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. Journal of Pharmacology and Experimental Therapeutics, 299, 775-781.
14. Larouche, J., Morais, J., Picard, M., Lambert, C., Spenard, J., Landriault, H., Kennedy, G., & Poitras, P. (1995). Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine. Alimentary Pharmacology & Therapeutics, 9, 315-320.
15. McLeod, A. D., Friend, D. R., & Tozer, T. N. (1993). Synthesis and chemical stability of glucocorticoid-dextran esters: potential prodrugs for colon-specific delivery. International Journal of Pharmaceutics, 92, 104-114.
16. McLeod, A. D., Friend, D. R., & Tozer, T. N. (1994). Glucocorticoid-dextran conjugates as potential prodrugs for colon-specific delivery: hydrolysis in rat gastrointestinal tract contents. Journal of Pharmaceutical Sciences, 83, 1284-1288.
17. Mehvar, R., Dann, R. O., & Hoganson, D. A. (2000). Kinetics of hydrolysis of dextran-methylprednisolone succinate, a macromolecular prodrug of methylprednisolone, in rat blood and liver lysosomes. Journal of Controlled Release, 68, 53-61.
18. Nakase, H., Okazaki, K., Tabata, Y., Uose, S., Ohana, M., Uchida, K., Matsushima, Y., Kawanami, C., Oshima, C., Ikada, Y., & Chiba, T. (2000). Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. Journal of Pharmacology and Experimental Therapeutics, 292, 15-21.
19. Pallone, F., Blanco Gdel, V., Vavassori, P., Monteleone, I., Fina, D., & Monteleone, G. (2003). Genetic and pathogenetic insights into inflammatory bowel disease. Current Gastroenterology Reports, 5, 487-492.
20. Shimoda, J., Onishi, H., & Machida, Y. (2001). Bioadhesive characteristics of chitosan microspheres to the mucosa of rat small intestine. Drug Development and Industrial Pharmacy, 27, 567-576.
21. Tabata, Y., & Ikada, Y. (1988). Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials, 9, 356-362.
22. Tabata, Y., Inoue, Y., & Ikada, Y. (1996). Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine, 14, 1677-1685.
23. Takishima, J., Onishi, H., & Machida, Y. (2002). Prolonged intestinal absorption of cephradine with chitosan-coated ethylcellulose microparticles in rats. Biological & Pharmaceutical Bulletin, 25, 1498-1502.
24. Tozaki, H., Odoriba, T., Okada, N., Fujita, T., Terabe, A., Suzuki, T., Okabe, S., Muranishi, S., & Yamamoto, A. (2002). Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. Journal of Controlled Release, 82, 51-61.
25. Watts, P. J., & Ilium, L. (1997). Colonic drug delivery. Drug Development and Industrial Pharmacy, 23, 893-913.
26. Watts, P. J., Barrow, L., Steed, K. P., Wilson, C. G., Spiller, R. C., Melia, C. D., & Davies, M. C. (1992). The transit rate of different sized model dosage forms through the human colon and the effects of a lactulose-induced catharsis. International Journal of Pharmaceutics, 87, 215-221.
27. Yano, H., Hirayama, F., Kamada, M., Arima, H., & Uekama, K. (2002). Colon-specific delivery of prednisolone-appended alpha-cyclodextrin conjugate: alleviation of systemic side effect after oral administration. Journal of Controlled Release, 79, 103-112.